Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by Northern Trust Corp

Northern Trust Corp grew its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 19.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,565 shares of the company’s stock after purchasing an additional 9,456 shares during the quarter. Northern Trust Corp owned approximately 0.12% of Ikena Oncology worth $94,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IKNA. JPMorgan Chase & Co. grew its stake in Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock worth $255,000 after acquiring an additional 154,892 shares during the period. Geode Capital Management LLC increased its position in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after purchasing an additional 56,936 shares during the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Ikena Oncology in the 4th quarter worth about $833,000. Gilead Sciences Inc. acquired a new position in shares of Ikena Oncology in the 4th quarter valued at about $3,294,000. Finally, BML Capital Management LLC boosted its stake in Ikena Oncology by 395.8% during the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock valued at $5,881,000 after purchasing an additional 2,862,578 shares during the period. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Ikena Oncology Price Performance

NASDAQ IKNA opened at $1.35 on Wednesday. Ikena Oncology, Inc. has a 12 month low of $0.97 and a 12 month high of $1.94. The company’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.40. The company has a market capitalization of $65.15 million, a P/E ratio of -1.10 and a beta of 0.47.

Ikena Oncology (NASDAQ:IKNA) last posted its earnings results on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, analysts anticipate that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.